tiprankstipranks

Nurix Therapeutics price target lowered to $32 from $35 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $35 and keeps an Outperform rating on the shares following quarterly results. The firm is updating opex estimates based on guidance from management. Oppenheimer believes the company’s cash position of about $550M and strategic collaborations can sustain operations into the first half of 2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue